Condition
Advanced Solid Tumors
Estimated Enrollment: 158
Age Group: 18 Years to 99 Years (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: M15-891|2016-002520-89
Study First Received: December 15, 2016
Last Updated: March 21, 2017
Estimated Primary Completion Date: June 2018
Primary Outcome Measures:
Number of participants with adverse events|Recommended Phase 2 Dose (RPTD) for ABBV-181|Maximum tolerated dose (MTD) of ABBV-181|Maximum observed serum concentration (Cmax)|Time to Cmax (Tmax)|Area under the serum concentration time curve (AUC)|Terminal half-life (t1/2)|Objective response rate (ORR)|Clinical benefit rate (CBR, defined as CR, PR or SD)|Progression-free survival (PFS)|Duration of objective response (DOR)
Sponsors and Collaborators:
AbbVie
Website Link: https://ClinicalTrials.gov/show/NCT03000257
